Abstract 1432P
Background
Lung cancer patients are vulnerable towards severe COVID-19 outcomes due to multiple risk factors such as smoking, older age or certain cancer treatments. During the COVID-19 pandemic the lung cancer care was significantly altered. As increasing data point towards a shift towards the diagnosis of more advanced tumors during the pandemic in lung cancer patients we evaluated cancer stages I-IV in lung cancer, especially NSCLC patients, newly diagnosed between 2018 and 2022 in a certified German lung cancer center.
Methods
Demographic data as well as tumor-related data were retrieved from the network oncology registry and evaluated retrospectively at the time of diagnosis. The study has been approved by the ethics committee of the Medical Association Berlin (Eth-27/10).
Results
In total 1118 lung cancer patients were included in the registry study. Comparing lung cancer patients from single pandemic years to the pre-pandemic year 2018, a significant 6.9% (p=0.02) drop of stage II lung cancer diagnoses was seen in 2022. Furthermore, when looking at NSCLC patients, significant tumor stage shifts were observed during 2021 and 2022: while the proportion of stage IV diagnosed NSCLC patients increased by 10.7% (p=0.03) during 2021, the proportion of stage II NSCLC decreased by 8.2% (p=0.01) in the following year compared to the pre-pandemic year 2018. No significant shifts were observed for SCLC patients. Finally yet importantly, a 12% decline of lung cancer diagnoses in 2021 and a 17.2% decline in 2022 was documented when comparing with diagnoses in 2018.
Conclusions
COVID-19-related delays and patient’s reluctance have led to clinically meaningful decreases of lung cancer diagnoses in a certified German lung cancer center. Additionally, a significant increase of stage IV NSCLC diagnosis (2021) and a significantly decreased diagnosis of stage II lung cancer, particularly NSCLC tumors (2022), during the COVID-19 pandemic were observed. The implication of these results on the cancer care, patient’s health-related quality of life and the lung cancer mortality will need to be urgently evaluated in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Research Institute Havelhöhe at the hospital Gemeinschaftskrankenhaus Havelhöhe.
Funding
AstraZeneca GmbH.
Disclosure
B.S. Matthes: Financial Interests, Institutional, Other, Travel cost: AstraZeneca GmbH, Boehringer Ingelheim AG & Co.; Financial Interests, Institutional, Other, Travel costs: Lilly Deutschland; Financial Interests, Institutional, Advisory Board: Janssen-Cilag GmbH, Novartis Pharma GmbH, MSD Sharp & Dohme GmbH, Gilead Sciences GmbH. C. Grah: Financial Interests, Institutional, Invited Speaker: AstraZeneca GmbH, Wala Heilmittel GmbH; Financial Interests, Institutional, Research Grant: Iscador AG. P. Grabowski: Financial Interests, Institutional, Invited Speaker: Ipsen Pharma, Helixor Heilmittel GmbH. F. Schad: Financial Interests, Institutional, Invited Speaker: AstraZeneca GmbH, Helixor Heilmittel GmbH; Financial Interests, Institutional, Funding: Abnoba GmbH, Iscador AG, Helixor Heilmittel GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20